TL
TLX
Telix Pharmaceuticals Ltd
$9.30
-2.52%
$3.2B
No data for this timeframe.
Vol
Market Cap$3.2B
Cap SizeMid Cap
Inst. Holders3 funds
Inst. Value$1.1M
Inst. Activity1 buys / 1 sells
Insider Activity2B / 0S
Insider Net $$996.7K
Press Releases8
Recent Activity
Apr 29, 2026
Insider
Behrenbruch Christian bought 33,435 shares
MD & Group CEO @ $14.87 ($497.2K)
Apr 28, 2026
Insider
Behrenbruch Christian bought 34,500 shares
MD & Group CEO @ $14.48 ($499.6K)
Mar 29, 2026
Insider
Smith Darren Charlton sold 1,111 shares
Group Chief Financial Officer @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — DOUBLED
17,653 shares ($132.2K)
Inst.
BANK OF AMERICA CORP — TRIM
1,608 shares ($12.0K)
Jun 2, 2026
Press
Telix Pharmaceuticals and United Imaging signed an MOU to evaluate a strategic research collaboration integrating Telix'
Impact 4/10
Jun 2, 2026
contract
Telix and United Imaging Announce Strategic Theranostics Collaboration
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIR
Jun 1, 2026
Press
Telix presented Phase 3 ProstACT Global Part 1 safety data at ASCO 2026 for TLX591-Tx in mCRPC, showing acceptable toler
Impact 6/10
Price Targets
$20.84
+124.0% upside
Strong Buy
Current $9.30
Low $19.69
Median $20.60
High $22.46
4 analysts
$19.69
$22.46
Analyst Ratings
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 13, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Apr 13, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 7, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Apr 7, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 24, 2026 | Citigroup | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.01 | $0.01 — $0.01 | 1 | |
| Next Q | $0.03 ▲ +107.1% | $0.03 — $0.03 | 1 | |
| Current FY | $0.13 ▲ +25.4% | $-0.01 — $0.24 | 540% YoY | 5 |
| Next FY | $0.33 ▼ -2.6% | $0.11 — $0.59 | 154% YoY | 4 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $925.5K | DOUBLED |
| MORGAN STANLEY | $132.2K | DOUBLED |
| BANK OF AMERICA CORP | $12.0K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 29, 2026 | Behrenbruch Christian | BUY | $497.2K |
| Apr 28, 2026 | Behrenbruch Christian | BUY | $499.6K |
| Mar 29, 2026 | Smith Darren | M | $0.00 |
| Mar 29, 2026 | Smith Darren | M | $0.00 |
3 institutional holders with $1.1M total value (142,831 shares) as of 2025-Q4. Top holders: FMR, MORGAN, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 123,570 | $925.5K | 86.5% | DOUBLED +181.5% |
| 2 | MORGAN STANLEY | 17,653 | $132.2K | 12.4% | DOUBLED +445.9% |
| 3 | BANK OF AMERICA CORP /DE/ | 1,608 | $12.0K | 1.1% | TRIM -25.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 3,234 | 17,653 | +445.9% | $132.2K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 2,150 | 1,608 | -25.2% | $12.0K | 2025-Q4 |
| FMR LLC | DOUBLED | 42,091 | 118,479 | +181.5% | $1.1M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 4,402 | 3,234 | -26.5% | $30.9K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEW | — | 2,150 | — | $20.6K | 2025-Q3 |
| FMR LLC | NEW | — | 42,091 | — | $680.6K | 2025-Q2 |
| UBS Group AG | ADD | 3,651 | 6,121 | +67.7% | $98.4K | 2025-Q2 |
| MORGAN STANLEY | NEW | — | 5,634 | — | $94.4K | 2025-Q1 |
| UBS Group AG | NEW | — | 3,730 | — | $57.4K | 2024-Q4 |
2 unique insiders with 2 transactions. Net insider value: $996.7K ($996.7K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 29, 2026 | Behrenbruch Christian | MD & Group CEO | BUY | 33,435 | $14.87 | $497.2K |
| Apr 28, 2026 | Behrenbruch Christian | MD & Group CEO | BUY | 34,500 | $14.48 | $499.6K |
| Mar 29, 2026 | Smith Darren Charlton | Group Chief Financial Officer | M | 1,111 | $0.00 | $0.00 |
| Mar 29, 2026 | Smith Darren Charlton | Group Chief Financial Officer | M | 1,111 | $0.00 | $0.00 |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
NEUTRAL
4/10
Telix Pharmaceuticals and United Imaging signed an MOU to evaluate a strategic research collaboratio
Jun 2, 2026
BULLISH
6/10
Telix presented Phase 3 ProstACT Global Part 1 safety data at ASCO 2026 for TLX591-Tx in mCRPC, show
Jun 1, 2026
BULLISH
6/10
Telix announced completion of patient enrollment in the Phase 1 IPAX-2 trial of TLX101-Tx for newly
May 18, 2026
NEUTRAL
4/10
Telix announced non-binding letters of intent to collaborate with EDAP TMS and Profound Medical, exp
May 15, 2026
BULLISH
5/10
Telix announced publication of exploratory Phase 3 ZIRCON data in European Urology showing TLX250-Px
May 4, 2026
BULLISH
7/10
Telix announces positive dosimetry data from Phase 2 OPTIMAL-PSMA trial of TLX597-Tx in mCRPC, showi
Apr 29, 2026
BULLISH
7/10
Telix Pharmaceuticals announced that safety and dosimetry data from Part 1 of its Phase 3 ProstACT G
Apr 21, 2026
BULLISH
7/10
Telix Pharmaceuticals announced a strategic collaboration with Regeneron to co-develop and co-commer
Apr 13, 2026
Analyst Price Targets
$20.84 mean target
+124.0% upside
Strong Buy (1.00)
$19.69 Low
$22.46 High
| Metric | Value |
|---|---|
| Current Price | $9.30 |
| Target Low | $19.69 |
| Target Mean | $20.84 |
| Target Median | $20.60 |
| Target High | $22.46 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.01 | $0.01 | $0.01 | — | — | 1↑ 0↓ | $0.3B | — | 1 |
| Next Q 2026-06-30 |
$0.03 | $0.03 | $0.03 | — | +107.1% | 1↑ 0↓ | $0.3B | — | 1 |
| Current FY 2026-12-31 |
$0.13 | $-0.01 | $0.24 | 539.8% | +25.4% | 2↑ 1↓ | $1.4B | 13.4% | 5 |
| Next FY 2027-12-31 |
$0.33 | $0.11 | $0.59 | 153.8% | -2.6% | 1↑ 1↓ | $1.6B | 17.1% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.014 | |
| 7d ago | $0.000 | +0.014 |
| 30d ago | $0.000 | +0.014 |
| 60d ago | $0.074 | -0.060 |
| 90d ago | $0.062 | -0.048 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 13, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Apr 13, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 7, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Apr 7, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 24, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 22, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
contract
Telix and United Imaging Announce Strategic Theranostics Collaboration
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NAS
Jun 1, 2026
fda
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "T
May 27, 2026
other
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Te
May 18, 2026
fda
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 19, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Te
May 15, 2026
contract
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Te
May 4, 2026
fda
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Te
Apr 30, 2026
other
TLX101-Px (Pixlumi®) MAA Accepted in Europe
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Te
Apr 29, 2026
fda
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS, April 30, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “
Apr 27, 2026
other
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “
Apr 21, 2026
fda
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “
Apr 14, 2026
fda
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “
Apr 13, 2026
contract
Telix and Regeneron Announce Strategic Radiopharma Collaboration
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS and TARRYTOWN, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:
Apr 9, 2026
fda
FDA Accepts NDA for TLX101-Px (Pixclara®)
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “
Apr 8, 2026
other
Telix Strengthens Board with Additional Director Appointments
<p>MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today an
Apr 6, 2026
earnings
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
<p align="justify">MELBOURNE, Australia and INDIANAPOLIS, April 07, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “